Jump to content
RemedySpot.com

Re: Secondary porphyria

Rate this topic


Guest guest

Recommended Posts

Guest guest

-

Sorry for the delay. I sent this info off before going

out of town, and just got back to email.

The info is from the Stratton patent materials and his

references to published studies is included there--

that's why I made sure to include the url so others

could check out his reasoning and argument for this.

He has a quite detailed and cogent explanation of this

issue, and his patent includes testing to sort out

primary (genetic) from secondary (caused by breakdown

of bacterial load under treatment) porphyria. It's not

" caused by abx " as I understand it, rather it is a

by-product of killing more bacterium than our body

detox pathways can handle, and therefore leaves

incompletely metabolized porphyric compounds which, in

themselves, are damaging.

I mostly wanted to add to our understanding of what a

" herx " could be, especially since he includes testing

methods which we can examine, and lot's of treatment

suggestions to counterbalance the oxidative and toxic

load.

Hope this helps,

Jim

From: " Schaafsma " <compucruz@...>

Subject: Re: Secondary Porphyria from antibacterial

treatment

Hi Jim, Did I miss the article which gives data

suggesting that

Porphyria results in some cases from antibacterial

treatment? Is

that a peer-reviewed, published finding?

Neurological symptoms which increase in response to

antibiotic

treatment might, you seem to be suggesting, be neither

the original

CNS infection nor a herx but an added condition

brought about by

antibiotic treatment.

That is a large claim, I would be very interested in

there were

published data supporting it. Also in qualifying it.

So that people

(like a majority of this list's participants, I'm

guessing) who have

taken or are taking long courses of antibiotics can

form some

conclusion about the liklihood of this being a concern

in their own

cases.

Is there reputable data which clarifies the scope of

the problem?

Thanks,

>> Hi all-

>> I got into providing this info for a discussion of

>> " neuro herx " on the Lyme Strategies list and

thought

>> it might add to the discussion here on herx vs

immune

>> cytokine release from bacterial die off vs

bacterial

>> endotoxin vs etc, etc. Now we can add porphyria to

the

>> list of things to sort out when we react to abx. So

>> I'm posting the info drawn from the sources noted.

>> Jim

>>

>> Kurt, et al—

>> Below is info on secondary porphyria taken from the

>> two sources identified in the links. The second

source

>> is from and Stratton's patent materials,

on

>> public record at the US patent office. Worth

reading

>> relating to Chlamydia problems, but also for their

>> meticulous and brilliant science on creating a

>> depthful and multifaceted approach to treating this

>> disease.

>>

>> I think I'll break this up into two posts in case

it's

>> too long.

>>

>> The description of porphyria (related to multiple

>> chemical sensitivity and chemical exposures) sure

>> sounds a lot like the " neuro herx " described on

this

>> list doesn't it?

>>

>> Secondary Porphyria Part I-

>> From:

>> http://www.mcsrr.org/resources/articles/S5.html

>> A secondary porphyrinuria or coprophyrinuria is a

>> porphyrin abnormality that occurs secondarily to

some

>> other disease which usually test positive for some

but

>> not all of the diagnostic markers associated with

true

>> porphyrias.

>>

>> The broader term " porphyrinopathy " is used here to

>> refer to any disorder of porphyrin metabolism,

>> inherited or acquired. The porphyrinopathies being

>> seen in chemically-sensitive patients do not fit

the

>> patterns of any known type of inherited porphyria.

>> This suggests that they may be the result of an

>> acquired abnormality, due either to the direct

effects

>> of a chemically-induced porphyrinopathy or the

>> secondary effects of some other disease.

>>

>> The " acute " porphyrias always display neurological

>> symptoms affecting the central, peripheral and/or

>> autonomic nervous systems. These may include any

>> combination of abdominal pain, nausea, vomiting,

>> constipation, seizures, headaches, difficulty

>> concentrating, personality changes, weakness and

>> aching in muscles and joints, unsteady gait, poor

>> coordination, numbness/ tingling of arms and legs,

>> retaining fluids, rapid heart rate, increased blood

>> pressure, increased sweating, and intermittent

fever.

>>

>> Acute and chemically-acquired cases also show

>> increased sensitivity to a long list of exposures

that

>> may both bring on symptoms and make them worse.

These

>> include certain medications (the focus of much

>> porphyria research), toxic chemicals (such as PCBs

and

>> dioxin), alcoholic beverages (including beer and

>> wine), other liver diseases (like Hepatitis C and

>> cancer) as well as more subtle factors like

hormonal

>> changes and a low carbohydrate diet. (Skipping

meals

>> and dieting make symptoms worse, while chemicals

that

>> mimic the female hormone estrogen are known to

trigger

>> acute porphyrias--both of which may contribute to

the

>> higher incidence of acute porphyrias in females.)

>>

>> Some persons with " acute " types of porphyria

excrete

>> porphyrin substances in the urine and/or stool only

in

>> response to exposures that make them ill. Their

tests

>> are more likely to show changes in the first 2 to 3

>> days after the onset of a reaction. Thus, urine and

>> stool testing is most sensitive and accurate during

>> that time.

>> Secondary Porphyria Part I-

>> From:

>> http://appft1.uspto.gov/netacgi/nph-Parser?

Sect1=PTO2 & Sect2=HITOFF & p=1 & u=%2Fnetahtml%2FPTO%2Fsearch-

bool.html & r=1 & f=G & l=50 & co1=AND & d=PG01 & s1=stratton & s2=chlamydia & OS=str

atton+AND+chlamydia & RS=stratton+AND+chlamydia

>> [0179] Treatment of Chlamydia infection may

>> [exaserbate] exacerbate secondary porphyria by

>> increasing the metabolism of cryptic Chlamydia or

by

>> accelerating the death of infected cells with

elevated

>> intracellular porphyrin levels.

>>

>> [0199]…The potential for secondary effects such as

>> porphyria should then be screened. For example,

this

>> can be evaluated by performing one or a combination

of

>> the following tests: 1) complete blood count

(CBC);

>> 2) Liver function tests; 3) Uric acid; 4) Serum

iron

>> studies; 5) IgM and IgG antibodies to

>> coproporpyrinogen-III and Vitamin B12; and, 6) ALA

>> dehydratase and PBG deaminase. Urine and stool

>> samples should also be tested for presence of

>> porphyrins, preferably using 24 hour samples.

>>

>> [0181] C. Therapies to Enhance Cellular Function

>>

>> [0182] Glucose is an important source of cellular

>> energy. Glucose levels can be enhanced by diet and

>> through vitamin supplements as described below.

>>

>> [0183] A high carbohydrate diet should be

maintained

>> to promote production of glucose (Pierach et al.,

>> Journal of the American Medical Association,

>> 257:60-61 (1987)). Approximately 70% of the caloric

>> intake should be in the form of complex

carbohydrates

>> such as bread, potato, rice and pasta. The

remaining

>> 30% of the daily diet should comprise protein and

fat,

>> which should ideally be in the form of fish or

>> chicken.

>> (ed. Absolutely avoid red meats! Worsens porphyria)

>>

>> [0181] C. Therapies to Enhance Cellular Function

>> [0182] Glucose is an important source of cellular

>> energy. Glucose levels can be enhanced by diet and

>> through vitamin supplements as described below.

>>

>> [0183] A high carbohydrate diet should be

maintained

>> to promote production of glucose (Pierach et al.,

>> Journal of the American Medical Association,

>> 257:60-61 (1987)). Approximately 70% of the caloric

>> intake should be in the form of complex

carbohydrates

>> such as bread, potato, rice and pasta. The

remaining

>> 30% of the daily diet should comprise protein and

fat,

>> which should ideally be in the form of fish or

>> chicken.

>>

>> [0188] Multivitamins containing the B complex

vitamins

>> should be administered daily (e.g., one or

multiple

>> times), preferably in excess of RDA, to enhance

>> glucose availability. Hepatic breakdown of glycogen

>> with generation of glucose is assisted by taking

>> these multivitamins that contain the B complex

>> vitamins. Pyridoxine minimizes the porphyrin

related

>> porphyrial neuropathy. B complex vitamins include

>> folic acid (e.g., 400 .mu.g per dosage; 1200 .mu.g

>> daily maximum); vitamin B-1 (thiamin; e.g., 10 mg

per

>> dosage; 30 mg daily maximum); B-2 (riboflavin;

e.g.,

>> 10 mg per dosage; 30 mg daily maximum); B-5

>> (panothenate; e.g., 100 mg per dosage; 300 mg

daily

>> maximum); B-6 (pyridoxine; e.g., 100 mg per dosage;

>> 300 mg daily maximum) or pyridoxal-5-phosphate

(e.g.,

>> 25 mg per dosage; 100 mg daily maximum) and B-12

>> (e.g., 500 .mu.g per dosage; 10,000 .mu.g daily

>> maximum). The preferred method of administration is

>> oral for the majority of these vitamins (twice

daily),

>> except for B-12 for which sublingual

administration

>> (three-times daily) is preferred. It has been

>> discovered that one important effect of this

secondary

>> porphyria in some patients is the production of

IgM

>> and IgG antibodies against coproporphyrinogen-III.

>> These antibodies cross-react with Vitamin B12

>> (cobalamin) and can thus cause a deficiency.

Vitamin

>> B12 supplementation (e.g., parenteral cobalamin

>> therapy) can remedy the deficiency.

>>

>> [0189] D. Reducing Porphyrin Levels

>> [0190] Dietary and pharmaceutical methods can be

used

>> to reduce systemic porphyrin levels (both

>> water-soluble and fat-soluble).

>>

>> [0191] Plenty of oral fluids in the form of

>> bicarbonated water or " sports drinks " (i.e., water

>> with glucose and salts) should be incorporated into

>> the regimen. This flushes water-soluble porphyrins

>> from the patient's system. Drinking seltzer water

is

>> the easiest way to achieve this goal. The color of

>> the urine should always be almost clear instead of

>> yellow. It is noted that dehydration concentrates

>> prophyrins and makes patients more symptomatic.

>>

>> [0192] Activated charcoal can be daily administered

in

>> an amount sufficient to absorb fat-soluble

porphyrins

>> from the enterohepatic circulation. Treatment with

>> activated oral is charcoal, which is nonabsorbable

>> and binds porphyrins in the gastrointestinal tract

and

>> hence interrupts their enterohepatic circulation,

has

>> been associated with a decrease of plasma and skin

>> porphyrin levels. Charcoal should be taken between

>> meals and without any other oral drugs or the

charcoal

>> will absorb the food or drugs rather than the

>> porphyrins. For those who have difficulty taking

the

>> charcoal due to other medications being taken

during

>> the day, the charcoal can be taken all at one time

>> before bed. Taking between 2 and 20 grams,

preferably

>> at least 6 grams (24.times.250 mg capsules) of

>> activated charcoal per day (Perlroth et al.,

>> Metabolism, 17:571-581 (1968)) is recommended.

Much

>> more charcoal can be safely taken; up to 20 grams

six

>> times a day for nine months has been taken without

>> any side effects.

>>

>> [0193] For severe porphyria, chelating and other

>> agents may be administered, singularly or in

>> combination, to reduce levels of porphyrins in the

>> blood. Examples of chelating agents include but are

>> not limited to Kemet (succimer; from about 10

mg/kg

>> to about 30 mg/kg); ethylene diamine tetracetic

acid

>> (EDTA); BAL (dimercaprol; e.g., 5 mg/kg maximum

>> tolerated dosage every four hours), edetate calcium

>> disodium (e.g., from about 1000 mg/m.sup.2 to

about

>> 5000 mg/m.sup.2 per day; can be used in

combination

>> with BAL); deferoxamine mesylate (e.g., from about

>> 500 mg to about 6000 mg per day); trientine

>> hydrochloride (e.g., from about 500 mg to about 3

g

>> per day); panhematin (e.g., from about 1 mg/kg to

>> about 6 mg/kg per day), penacillamine. Intravenous

>> hematin may also be administered. Quinine

>> derivatives, such as but limited to

>> hydroxychloroquine, chloroquine and quinacrine,

should

>> be administered to the patient daily at a dosage

of

>> from about 100 mg to about 400 mg per day,

preferably

>> about 200 mg once or twice per day with a maximum

>> daily dose of 1 g. Hydrochloroquine is most

>> preferred. The mechanism of action of

>> hydroxychloroquine is thought to involve the

formation

>> of a water-soluble drug-porphyria complex which is

>> removed from the liver and excreted in the urine

>> (Tschudy et al., Metabolism, 13:396-406 (1964);

>> Primstone et al., The New England Journal of

Medicine,

>> 316:390-393 (1987)).

>>

>> [0194] To reduce severe porphyric attacks during

>> therapy for chronic Chlamydia infections, the use

of

>> hemodialysis, plasmapheresis, chelating agents

and/or

>> intravenous hematin may be needed. Any one of these

or

>> a combination thereof can be used to treat the

>> patient and is well within the knowledge of the

>> skilled artisan how to carry out these adjunct

>> therapies.

>>

>> [0195] E. Mitigating the Effects of Porphyrins

>>

>> [0196] Antioxidants at high dosages (preferably

taken

>> twice per day) help to mitigate the effects of

free

>> radicals produced by porphyrins. Examples of

suitable

>> antioxidants include but are not limited to Vitamin

C

>> (e.g., 1 gram per dosage; 10 g daily maximum);

>> Vitamin E (e.g., 400 units per dosage; 3000 daily

>> maximum); L-Carnitine (e.g., 500 mg per dosage; 3 g

>> daily maximum); coenzyme Q-10 (uniquinone (e.g., 30

mg

>> per dosage; 200 mg daily maximum); biotin (e.g., 5

mg

>> per dosage; 20 mg daily maximum); lipoic acid

(e.g.,

>> 400 mg per dosage; 1 g daily maximum); selenium

(e.g.,

>> 100 .mu.g per dosage; 300 .mu.g daily maximum);

>> gultamine (e.g., from 2 to about 4 g per dosage);

>> glucosamine (e.g., from about 750 to about 1000 mg

>> per dosage); and chondroitin sulfate (e.g., from

about

>> 250 to about 500 mg per dosage).

>>

>> [0197] The above-mentioned therapeutic diets can be

>> combined with traditional or currently recognized

>> drug therapies for porphyria. In one embodiment,

>> benzodiazapine drugs, such as but not limited to

>> valium, klonafin, flurazepam hydrochloride (e.g.,

>> Dalmanc.TM., Roche) and alprazolam (e.g., Xanax),

can

>> be administered. Preferably, sedatives, such as

>> alprazolam (e.g., Xanax; 0.5 mg per dosage for 3 to

4

>> times daily), can be prescribed for panic attacks

and

>> flurazepam hydrochloride (e.g., Dalmane.TM., Roche

or

>> Restoril.TM. (e.g., 30 mg per dosage)) can be

>> prescribed for sleeping. The rationale is based

upon

>> the presence of peripheral benzodiazepine

receptors

>> in high quantities in phagocytic cells known to

>> produce high levels of radical oxygen species. A

>> protective role against hydrogen peroxide has been

>> demonstrated for peripheral benzodiazipine

receptors.

>> This suggests that these receptors may prevent

>> mitochondria from radical damages and thereby

regulate

>> apoptosis in the hematopoietic system.

>> Benzodiazepines have also been shown to interfere

>> with the intracellular circulation of heme and

>> porphyrinogens (Scholnick et al., Journal of

>> Investigative Dermatology, 1973, 61:226-232). This

is

>> likely to decrease porphyrins and their adverse

>> effects. The specific benzodiazipine will depend on

>> the porphyrin-related symptoms.

>>

>> [0198] Cimetidine can also be administered

separately

>> or in combination with benzodiazepine drugs.

>> Cimetidine has been shown to effectively scavenge

>> hydroxyl radicals although it is an ineffective

>> scavenger for superoxide anion and hydrogen

peroxide.

>> Cimetidine appears to be able to bind and

inactivate

>> iron, which further emphasizes its antioxidant

>> capacity. Cimetidine also is an effective scavenger

>> for hypochlorous acid and monochloramine, which

are

>> cytotoxic oxidants arising from inflammatory

cells,

>> such as neutrophils. Cimetidine thus would be

>> expected to be useful for the therapy of

>> free-radical-mediated oxidative damage caused by

>> chlamydial porphyria. Recent studies in Japan have

>> found that cimetadine is effective for treating

>> porphyria. The recommended amount of cimetadine is

>> about 400 mg once or twice per day.

________________________________________________________________________

___________

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...